Mostrar el registro sencillo

dc.contributor.authorDe la Fuente Vivas, Dalia
dc.contributor.authorCappitelli, Vincenzo
dc.contributor.authorGarcía Gómez, Rocío
dc.contributor.authorValero Díaz, Sara
dc.contributor.authorAmato, Camilla
dc.contributor.authorRodríguez, Javier
dc.contributor.authorDuro-Sánchez, Santiago
dc.contributor.authorKriegsheim, Alexander von
dc.contributor.authorGrusch, Michael
dc.contributor.authorLozano, José
dc.contributor.authorArribas, Joaquín
dc.contributor.authorCasar Martínez, Berta
dc.contributor.authorCrespo, Piero
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2025-07-11T08:25:40Z
dc.date.available2025-07-11T08:25:40Z
dc.date.issued2025
dc.identifier.issn1574-7891
dc.identifier.issn1878-0261
dc.identifier.otherPDC2022-133569-I00es_ES
dc.identifier.otherPID2021-126288OB-I00es_ES
dc.identifier.otherPID2020/112760RB-100es_ES
dc.identifier.urihttps://hdl.handle.net/10902/36664
dc.description.abstractERK1/2 mitogen-activated protein kinases (ERK) are key regulators of basic cellular processes, including proliferation, survival, and migration. Upon phosphorylation, ERK becomes activated and a portion of it dimerizes. The importance of ERK activation in specific cellular events is generally well documented, but the role played by dimerization is largely unknown. Here, we demonstrate that impeding ERK dimerization precludes cellular movement by interfering with the molecular machinery that executes the rearrangements of the actin cytoskeleton. We also show that a constitutively dimeric ERK mutant can drive cell motility per se, demonstrating that ERK dimerization is both necessary and sufficient for inducing cellular migration. Importantly, we unveil that the scaffold protein kinase suppressor of Ras 1 (KSR1) is a critical element for endowing external agonists, acting through tyrosine kinase receptors, with the capacity to induce ERK dimerization and, subsequently, to unleash cellular motion. In agreement, clinical data disclose that high KSR1 expression levels correlate with greater metastatic potential and adverse evolution of mammary tumors. Overall, our results portray both ERK dimerization and KSR1 as essential factors for the regulation of cell motility and mammary tumor dissemination.es_ES
dc.description.sponsorshipWe are indebted to Dr D. Engelberg for providing reagents. PC lab is supported by grant PID2021- 126288OB-I00 and PDC2022-133569-I00 from the Spanish Ministry of Science (MICIU/AEI/FEDER, UE); CIBERONC (CB16/12/00436) from the Instituto de Salud Carlos III (ISCIII); and a grant from ASPLA S.A “Encintalo en Rosa” Initiative. BC is funded by grants from Ministerio de Innovación, Ciencia y Universidades, MICIU PID2020/112760RB-100 and La Fundació d’Estudis i Recerca Oncológica (FERO, BFERO2021.03). JA is supported by CIBERONC; Breast Cancer Research Foundation (BCRF-23-008) and Instituto de Salud Carlos III (ISCIII) (PI22/ 00001). AK is supported by the Wellcome Trust (Multiuser Equipment Grant, 208402/Z/17/Z). DF-V is a CIBERONC predoctoral fellow (JCSTF2105526).es_ES
dc.format.extent22 p.es_ES
dc.language.isoenges_ES
dc.publisherJohn Wiley & Sonses_ES
dc.rights© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. This is an open access article under the terms of the Creative Commons Attribution Licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceMolecular Oncology, 2025, 19(2), 452-473es_ES
dc.subject.otherCell motilityes_ES
dc.subject.otherERKes_ES
dc.subject.otherKSRes_ES
dc.subject.otherMAP kinaseses_ES
dc.subject.otherScaffold proteinses_ES
dc.titleERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motilityes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1002/1878-0261.13732es_ES
dc.rights.accessRightsopenAccesses_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PDC2022-133569-I00/ES/DESARROLLO DE UN BIOMARCADOR DE LA RESPUESTA TERAPEUTICA DEL MELANOMA BRAF POSITIVOes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2021-126288OB-I00/ES/PROTEINAS HOX COMO MEDIADORES DE LAS SEÑALES DE LA RUTA RAS_ERKes_ES
dc.identifier.DOI10.1002/1878-0261.13732
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. This is an open access article under the terms of the Creative Commons Attribution LicenseExcepto si se señala otra cosa, la licencia del ítem se describe como © 2024 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. This is an open access article under the terms of the Creative Commons Attribution License